HSP90AB1 and neoplasm: In patients with advanced colorectal cancer, the group with a high expression of HSP90α/β in the tumor had a significantly worse prognosis, but paradoxically, the treatment response to the HSP90 inhibitor pimitesrib was better, showing an enhanced effect especially when administered in combination with chemotherapy or targeted therapy [148].